



JPW

DECKET NO.: CELG-0422

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jerome B. Zeldis, et al.

Application No.: 10/820,397

Filing Date: April 8, 2004

For: **METHODS FOR TREATMENT OF COGNITIVE AND MENOPAUSAL
DISORDERS WITH D-THREO METHYLPHENIDATE**

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: May 11, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- ☒ In view of the voluminous nature of reference 64, and the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
 - ☒ Copies of references **1-29, 71-82 and 89-91** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **08/583,317**, filed **January 5, 1996** now **U.S. Patent No. 5,773,756**; copies of references **83-86** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/318,151**, filed **May 25, 1999** now **U.S. Patent No. 6,355,656**; copies of references **30-70, 87-88 and 92** listed on the attached Form PTO-1449 were previously cited by or

DOCKET NO.: CELG-0422

- 4 -

PATENT


submitted to the Patent and Trademark Office in prior
Application No. 10/195,974, filed July 16, 2002 now
Publication No. 2002-0198234 A1.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-
3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date:

May 11, 2004


Richard D. Watkins
Registration No. 50,993

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	1	Angrist, et al., <i>Journal of Clinical Psychopharmacology</i> , 1992 , 12, 268-272	
	2	Aoyama, et al., "Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia," <i>Clin. Pharmacol. Ther.</i> , 1994 , 55, 270-276	
	3	Barkley, et al., <i>Pediatrics</i> , 1990 , 86, 184-192	
	4	Barkley, et al., <i>Pediatrics</i> , 1991 , 87, 519-531	
	5	Bowden, K., et al., "Reactions of carbonyl compounds in basic solutions, Part 15. The alkaline hydrolysis of N-methyl, N-phenyl, and bicycle lactams, penicillins, and n-alkyl-N-methylacetamides," <i>J. Chem. Soc. Perkin Trans.</i> , 1990 , 2(12), 2111-2116	
	6	Brown, C., "Pharmacological action and drug development," <i>Chirality in Drug Design and Synthesis</i> , Academic Press, Inc., 1990 , 4-7	
	7	Brown, G., "The use of methylphenidate for cognitive decline associated with HIV disease," <i>Int'l. J. Psychiatry Med.</i> , 1995 , 25(1), 21-37	
	8	Corey, et al., "A new synthetic approach to the penicillins," <i>J. Amer. Chem. Soc.</i> , 1965 , 87(11), 2518	
	9	Ding, L.K., et al., "Cis- and trans-azetidin-2-ones from nitrones and copper acetylides," <i>J. Chem. Soc. Perkin I</i> , 1976 , 22, 2382-2386	
/D.S./	10	Douzenis, et al., "Psychiatric disorder in HIV disease: description of 200 referrals to a liaison psychiatry service," <i>Proc. 7th Int'l Conf. AIDS</i> , 1991 , 215 (M.B.2135—Summary)	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	11	Earle, et al., "synthesis and hydrolysis of some fused-ring. Beta.-lactams," <i>J. Chem. Soc.</i> , 1969 , 2093-2098	
	12	Golinko, <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat</i> , 1984 , 8, 1-8	
	13	Greenhill, Pharmacologic treatment of attention deficit hyperactivity disorder," <i>Pediatric Psychopharmacology</i> , 1992 , 15(1), 1-27	
	14	Greenhill, L., "Attention-deficit hyperactivity disorder," <i>Child & Adol. Psych. Clin. N.A.</i> , 1995 , 4, 123-165	
	15	Holmes, et al., "Psychostimulant response in aids-related complex patients," <i>J. Clin. Psychiatry</i> , Biosis Abstract No. 87129969, 1987 , 50(1), 5-8	
	16	Hou, J.P., et al., "Beta-lactam antibiotics: their physicochemical properties and biological activities in relation to structure," <i>J. Pharm. Sci.</i> , 1971 , 60(4), 503-532	
	17	Klibanov, A.M., "Asymmetric transformations catalyzed by enzymes in organic solvents," <i>Acc. Chem. Res.</i> , 1990 , 23, 114-120	
	18	Moll, F., "Darstellung von 1-aza-bicyclo[4.2.0]octan-2-on," <i>Naturforsch teil B.</i> , 1996 , 21, 297	
	19	Navia, et al., "The AIDS dementia complex: I. clinical features," <i>Annals of Neurology</i> , 1986 , 19, 517-524	
/D.S./	20	Patrick, et al., "Pharmacology of the enantiomers of threo-methylphenidate," <i>J. Pharmacol. & Exp. Terhap.</i> , 1987 , 241, 152-158	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	21	Rieder, et al., "Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge," with hydroxylamine metabolites," <i>Ann. Intern. Med.</i> , 1989 , <i>110</i> , 286-289	
	22	Scott, "Stereoisomers and drug toxicity," <i>Drug Safety</i> , 1993 , <i>8</i> , 149-159	
	23	Srinivas, et al., "Enantiomeric gas chromatography assay with electron capture detection for d-ritalinic acid in plasma," <i>J. Chromatograph</i> , 1990 , <i>530</i> , 327-336	
	24	Srinivas, et al., "Sterioseleective disposition of methylphenidate in children with attention deficit disorder," <i>J. Pharmacol. Exp. Ther.</i> , 1987 , <i>241</i> , 300-306	
	25	Srinivas, et al., "Enantioselective pharmacokinetics and Pharmacodynamics of racemic threo-methylphenidate in children with attention deficit hyperactivity disorder," <i>Clin. Pharmacol. Ther.</i> , Biosis Abstract No. 9506 1995 , <i>6168</i> , <i>52(2)</i> , 561-568	
	26	Srinivas, et al., "Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans," <i>Pharmacol. Res.</i> , 1993 , <i>10(1)</i> , 14-21	
	27	Staal, et al. "glutathione deficiency and human immunodeficiency virus infection," <i>Lancet</i> , 1992 , <i>339</i> , 909-912	
	28	Uetrecht, et al., "Idiosyncratic drug reactions: Possible role of reactive metabolites generated by leukocytes," <i>Pharmacol. Res.</i> , 1989 , <i>6(4)</i> , 265-273	
	29	White, et al., "Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: An n-of-1 trial," <i>J. Clin. Psychiatry</i> , 1992 , <i>53(5)</i> , 153-156	
/D.S./	30	Abwal, H.A., et al., "The effects of methylphenidate (MP) on narcotic-induced cognitive failure (MICF)," <i>Am. Soc. Clin. Oncology</i> , 27 th Annual Meeting, May 19-21, 1991, <i>1385</i> , 1992 , <i>Vol. 11</i> , page 397	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	31	"Attention-deficit and disruptive behavior disorders: Attention-deficit/hyperactivity disorder," American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, <i>Fourth Ed. (DSM-IV)</i> Washington, DC, 1994, 78-85	
	32	Beck, A.T., et al., "Assessment of depression: the depression inventory," <i>Mod. Probl. Pharmacopsychiatry</i> , 1974, 7, 155-169	
	33	Brown, T.E., "Attention deficit disorders and comorbidities in children, adolescents and adults," <i>American Psychiatric Press, Washington, DC</i> , 2000, 40-41	
	34	Brown, T.E., "Emerging understandings of attention-deficit disorders and comorbidities," Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults, <i>American Psychiatric Press, Inc.</i> , 2000, Chapter 1, 3-55	
	35	Bruera, E., et al., "Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain," <i>Pain</i> , 1992, 48, 163-166	
	36	Bruera, E., et al., "Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer," <i>J. Pain and Symptom Management</i> , March 1989, 4(1), 3-6	
	37	Bruera, E., et al., "Overwhelming fatigue in advanced cancer," <i>Am. J. Nursing, Pain Consult</i> , January 1988, 99-100	
	38	Bruera, E., et al., "Narcotics plus methylphenidate (ritalin) for advanced cancer pain," <i>Am. J. Nursing, Pain and Symptom Consult</i> , November 1988, 1665-1666	
	39	Bruera, E., et al., "The use of methylphenidate in patients with incident cancer pain receiving regular opiates, A preliminary report," <i>Pain</i> , ISSN 0304-3959, July 1992, 50(1), 75-77	
/D.S./	40	Bruera, E., "Methylphenidate associated with narcotics for the treatment of cancer pain," <i>Cancer Treatment Reports</i> , January 1987, 71(1), 67-70	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	41	Bruera, E., "Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain," <i>Pain</i> , February 1992, ISSN 0304-3959, 48(2), 163-166	
	42	Cella, D.F., et al., "The functional assessment of cancer therapy scale: development and validation of the general measure," <i>J. Clin. Oncol.</i> , 1993, 11(3), 570-579	
	43	DeLong, R., et al., "Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia," <i>J. Child Neurology</i> , October 1992, 7, 462-463	
	44	Faust, D., et al., "The development and initial validation of a sensitive bedside cognitive screening test," <i>J. Nerv. Ment. Dis.</i> , 1989, 177(1), 25-31	
	45	Fernandez, F., et al., "Methylphenidate for depressive disorders in cancer patients," <i>Psychosomatics</i> , September 1987, 28(9), 455-461	
	46	Fernandez, F., et al., "Methylphenidate treatment for patients with head and neck cancer," <i>Head and Neck Surgery</i> , March/April 1986, 8(4), 296-300	
	47	Folstein, S.E., et al., "Minimental state": a practical method for grading the cognitive state of patients for the clinician," <i>J. Psychiatry Res.</i> , 1975, 12, 189-198	
	48	Hales, R.E., et al., "Psychopharmacologic issues in the diagnosis and treatment of organic mental disorders," <i>Psychia. Clinics of North America</i> , December 1984, 7(4), 817-829	
	49	Kaplan, E.F., et al., "The Boston Naming Test, Boston, 1978	
/D.S./	50	Macleod, A.D., et al., "Methylphenidate in terminal depression," <i>J. Pain and Symptom Management</i> , September 1998, 16(3), 193-198	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	51	Massie, M.J., et al., "Diagnosis and treatment of depression in the cancer patient," <i>Clinical Psychiatry</i> , March 1984, Vol. 45, 3(2), 25-29	
	52	Meyers, C.A., et al., "Methylphenidate therapy improves cognition, mood, and function of brain tumor patients," <i>J. Clinical Oncology</i> , July 1998, 16(7), 2522-2527	
	53	Nakano, T., et al., Algorithm for the treatment of major depression in patients with advanced cancer," <i>Psychiatry and Clinical Neurosciences</i> , Proceedings of the International Meeting on Japanese Psychopharmacology Algorithms Yokohama, April 23, 1998, ISSN1323-1316, 1999, Supplement 53, S61-S65	
	54	Olin, J., et al., "Psychostimulants for depression in hospitalized cancer patients," <i>Psychosomatics</i> , January-February 1996, 37(1), 57-62	
	55	O'Neill, W.M., "The cognitive and psychomotor effects of opioid drugs in cancer pain management," <i>Cancer Surveys</i> , Palliative Medicine Problem Areas in Pain and Symptom Management, 1994, 21, 67-84	
	56	Plutchik, L., et al., "Methylphenidate in post liver transplant patients," <i>Psychosomatics</i> , March-April 1998, 39(2), 119-123	
	57	Portenoy, R.K. (Ed.), "Worth Repeating: Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer," <i>Pharmacology</i> , year unknown, 2 pages	
	58	Radloff, L.S., "The CES-D scale: a self-report depression scale for research in the general population," <i>Applied Psychological Measurement</i> , Summer 1977, 1(3), 385-401	
	59	Reich, M.G., "Amphetamines in oncology: review of the literature," <i>Cancer</i> , 1996, 83, 891-900 (English abstract)	
/D.S./	60	Reitan, R.M., "Validity of the trail making test as an indicator of organic brain damage," <i>Perceptual Motor Skills</i> , 1958, 8, 271-276	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	61	Roehrs, T., et al., "Sleepiness and the reinforcing and subjective effects of methylphenidate," <i>Exp. Clin. Psychopharmacol</i> , 1999, 7(2), 145-150 (Abstract 1 page)	
	62	Stiebel, V., et al., "Long-term methylphenidate use in the medically ill patient with organic mood syndrome," <i>Psychosomatics</i> , Fall 1990, 31(4), 454-456	
	63	Vigano, A., et al., "Methylphenidate for the management of somatization in terminal cancer patients," <i>J. Pain and Symptom Management</i> , February 1995, 10(2), 167-170	
*	64	Wechsler D., "Wechsler Adult Intelligence Scale-Revised Manual, New York, Psychological Corporation, 1981	
	65	Weitzner, M.A., et al., "The functional assessment of cancer therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors," <i>Cancer</i> , March 1, 1995, 75(5), 1151-1161	
	66	Weitzner, M.A., et al., "Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment," <i>J. Neuropsychiatry</i> , Summer 1995, 7(3), 347-350	
	67	Wilens, T.E., et al., "Pharmacotherapy of attention-deficit/hyperactivity disorder," <i>Attention-Deficit Disorders with Comorbidities</i> , Chapter 16, 509-535	
	68	Wilwerding, M.B., et al., "A randomized crossover evaluation of methylphenidate in cancer patients receiving strong narcotics," <i>Am. Soc. Clin. Oncology</i> , 29 th Annual Meeting May 16-18, 1993, 1615, 1993, Vol. 12, page 464	
	69	Yee, J.D., et al., "Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer," <i>J. Pain and Symptom Management</i> , February 1994, 9(2), 122-125	
/D.S./	70	Yellin, S.B., et al., "Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system," <i>J. pain Symptom Manage.</i> , February 1997, 13(2), 63-74	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. CELG-0422		Application No. 10/820,397	
				Applicant Jerome B. Zeldis, et al.			
				Filing Date April 8, 2004		Group Not Yet Assigned	
				Confirmation No. Not Yet Assigned			
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
/D.S./	71	2,507,631	05/1950	Hartmann, et al.	260	294	
	72	2,957,880	10/1960	Rometsch	546	233	
	73	4,992,445	02/1991	Lawter, et al.	514	279	
	74	5,104,899	04/1992	Young, et al.	514	646	
	75	5,114,946	05/1992	Lawter, et al.	514	279	
	76	5,217,718	06/1993	Colley, et al.	424	449	
	77	5,283,193	02/1994	Yamamoto, et al.	435	280	
	78	5,284,769	02/1994	Evans, et al.	435	280	
	79	5,331,000	07/1994	Young, et al.	514	570	
	80	5,362,755	11/1994	Barberich, et al.	514	649	
	81	5,375,693	12/1994	Woosley, et al.	514	317	
	82	5,449,743	09/1995	Kobayashi, et al.	528	355	
	83	5,773,478	06/1998	Richards, et al.	514	649	
	84	5,837,284	11/1998	Mehta, et al.	424	459	
	85	5,874,090	02/1999	Baker, et al.	424	600	
	86	5,908,850	06/1999	Zeitlin, et al.	514	315	
	87	5,733,756	03/31/98	Zeitlin, et al.	435	122	
/D.S./	88	6,486,177	11/2002	Zeldis, et al.	514	317	
EXAMINER /Darryl Sutton/				DATE CONSIDERED 03/14/2008			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. CELG-0422		Application No. 10/820,397	
				Applicant Jerome B. Zeldis, et al.			
				Filing Date April 8, 2004		Group Not Yet Assigned	
				Confirmation No. Not Yet Assigned			
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
/D.S./	89	WO 97/03671	02/1997	PCT			
	90	WO 97/03672	02/1997	PCT			
	91	WO 97/03673	02/1997	PCT			
/D.S./	92	WO 98/23263	06/04/98	PCT			
EXAMINER	/Darryl Sutton/			DATE CONSIDERED	03/14/2008		